Lantern Pharma plans Phase 1b/2a trial of LP-184 plus spironolactone in recurrent glioblastoma
LTRN•Lantern Pharma plans a Phase 1b/2a trial combining LP-184 and spironolactone in recurrent glioblastoma. Published Phase 1a results showed no objective tumor responses, and limited brain exposure constrained LP-184’s potential as a standalone therapy.
1. Planned combination trial
Lantern Pharma said its subsidiary Starlight Therapeutics will sponsor a planned Phase 1b/2a trial of LP-184 plus spironolactone in patients with glioblastoma at first recurrence following standard therapy. Phase 1a results, published in the October 2026 issue of Cancer Research Communications, found treatment was generally well tolerated but produced no objective tumor responses; preclinical findings support combining the drugs to increase tumor sensitivity rather than raising the dose.
